Share Article
"This phase 2 study in r/r MCL will address an unmet need in patients who have failed prior therapies," said Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer. "In addition to ZUMA-1 in refractory, aggressive
ZUMA-2 will proceed as a single arm, open-label, multi-center study, designed to determine the efficacy and safety of KTE-C19 in patients with MCL whose disease is refractory to or has relapsed following anthracycline- or bendamustine-containing chemotherapy and anti-CD20 monoclonal antibody therapy and ibrutinib. This study plans to enroll 70 subjects. Additional details about this study will soon be posted to ClinicalTrials.gov.
About
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the timing of initiating two additional pivotal KTE-C19 studies in acute lymphoblastic leukemia (ALL), and the ability to obtain regulatory approval based on the studies of KTE-C19. Various factors may cause differences between Kite's expectations and actual results as discussed in greater detail in Kite's filings with the
CONTACT:Source:Kite Pharma Cynthia M. Butitta Chief Financial Officer and Chief Operating Officer 310-824-9999 For Media:Justin Jackson For Investor Inquiries:Lisa Burns Burns McClellan 212-213-0006 jjackson@burnsmc.comlburns@burnsmc.com
News Provided by Acquire Media
Other News
Some of the content on this page is not intended for users outside the U.S.